Long acting Liraglutide - Nanexa
Alternative Names: NEX-22; NEX-22ALatest Information Update: 14 Oct 2025
At a glance
- Originator Nanexa
- Class Anti-inflammatories; Antihyperglycaemics; Antiparkinsonians; Antirheumatics; Glucagon-like peptides; Obesity therapies
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Type 2 diabetes mellitus
Most Recent Events
- 18 Jul 2025 Nanexa completes a phase-I clinical trials in Type 2 diabetes mellitus (Treatment-experienced) in Germany (SC) (NCT06439056)
- 20 Jun 2025 Pharmacokinetics and adverse events data from a phase I trial in Type 2 diabetes mellitus presented at the 85th Annual Scientific Sessions of the American Diabetes Association (ADA-2025)
- 07 Jun 2024 Nanexa has patents protection relating to its PharmaShell® technology in India, China, South Korea, China and the US